Sign In
Free Newsletter
Cooper Foundation Red Hot Gala raises $4M for health care
The annual bash supports the work and expansion of Cooper University Health Care. This year's event paid tribute to longtime backers Donna and Rick Forman.
New NJ cancer center brings home advanced care – and hope
Now open, the $1 billion, 12-story Jack & Sheryl Morris Cancer Center in New Brunswick is New Jersey’s first and only freestanding cancer hospital.
NJBIZ Conversations: SpotitEarly CEO Shlomi Madar
The chief executive officer describes the company's canine diagnostic technology and where it goes from here.
RWJBarnabas names new CFO for Rutgers Cancer Institute
An executive from another National Cancer Institute-designated Comprehensive Cancer Center will succeed Linda Tanzer, who will retire after 30 years this spring.
Lisata Therapeutics embarks on cancer-fighting campaign
The Basking Ridge-based firm is making strides against the disease using innovative technology to develop treatments that weaken tumors and potentially enhancing the delivery of drugs.
$6.3M supports new Rutgers Cancer Institute endowed directorship (updated)
The designation is named for Dr. William “Bill” Hait, the executive vice president, chief external innovation and medical officer for Johnson & Johnson, as well as RCI's founding director.
Quest completes acquisition of PathAI diagnostics assets
As part of the deal, the Secaucus-based testing provider bought out the company's lab in Memphis and rebranded the facility as AmeriPath.
Quest plans to purchase PathAI’s diagnostic lab as part of AI ramp-up
“AI and digital technologies have tremendous potential to improve cancer care, and Quest has the know-how to scale and deliver innovations that are high quality, efficient and broadly accessible," said Quest Senior Vice President of Oncology Kristie Dolan.
3 Camden organizations pledge $30M to create ‘one-of-a-kind’ cancer center
The Coriell Institute for Medical Research, Cooper University Health Care and Cooper Medical School of Rowan University joined forces with the goal of improving care in South Jersey and, eventually, worldwide.
Teva launches first generic for rare cancer treatment Revlimid
Revlimid – which had annual sales of $2.3 billion as of December 2021, according to IQVIA data – is used for myelodysplastic syndrome, multiple myeloma, and mantle cell lymphoma.
